SUSAN HILSENBECK to Biomarkers, Tumor
This is a "connection" page, showing publications SUSAN HILSENBECK has written about Biomarkers, Tumor.
Connection Strength
1.160
-
HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade. J Natl Cancer Inst. 2020 01 01; 112(1):46-54.
Score: 0.095
-
Biomarkers in benign breast disease: risk factors for breast cancer. J Natl Cancer Inst. 1998 Sep 02; 90(17):1247-8.
Score: 0.087
-
Modernizing Eligibility Criteria for Molecularly Driven Trials. J Clin Oncol. 2015 Sep 01; 33(25):2815-20.
Score: 0.070
-
Effects of TP53 mutational status on gene expression patterns across 10 human cancer types. J Pathol. 2014 Apr; 232(5):522-33.
Score: 0.063
-
Surrogate endpoints in chemoprevention of breast cancer: guidelines for evaluation of new biomarkers. J Cell Biochem Suppl. 1993; 17G:205-11.
Score: 0.058
-
Comparison of three tumor markers--CA-125, lipid-associated sialic acid (LSA), and NB/70K--in monitoring ovarian cancer. Gynecol Oncol. 1990 Aug; 38(2):181-6.
Score: 0.049
-
Nuclear IRS-1 predicts tamoxifen response in patients with early breast cancer. Breast Cancer Res Treat. 2010 Oct; 123(3):651-60.
Score: 0.047
-
Effect of lapatinib on the development of estrogen receptor-negative mammary tumors in mice. J Natl Cancer Inst. 2009 Jan 21; 101(2):107-13.
Score: 0.044
-
Low SAFB levels are associated with worse outcome in breast cancer patients. Breast Cancer Res Treat. 2010 Jun; 121(2):503-9.
Score: 0.044
-
Identification of tumor-initiating cells in a p53-null mouse model of breast cancer. Cancer Res. 2008 Jun 15; 68(12):4674-82.
Score: 0.043
-
Molecular profiles of progesterone receptor loss in human breast tumors. Breast Cancer Res Treat. 2009 Mar; 114(2):287-99.
Score: 0.042
-
Wnt-1 is dominant over neu in specifying mammary tumor expression profiles. Technol Cancer Res Treat. 2006 Dec; 5(6):565-71.
Score: 0.038
-
Gene expression patterns for doxorubicin (Adriamycin) and cyclophosphamide (cytoxan) (AC) response and resistance. Breast Cancer Res Treat. 2006 Feb; 95(3):229-33.
Score: 0.036
-
Genomic approaches in the management and treatment of breast cancer. Br J Cancer. 2005 Feb 28; 92(4):618-24.
Score: 0.034
-
PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast Cancer. Mol Cancer Ther. 2024 Oct 01; 23(10):1494-1510.
Score: 0.033
-
A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2+ Breast Cancer. Clin Cancer Res. 2023 08 15; 29(16):3101-3109.
Score: 0.030
-
Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst. 2003 Mar 05; 95(5):353-61.
Score: 0.030
-
Mouse-INtraDuctal (MIND): an in vivo model for studying the underlying mechanisms of DCIS malignancy. J Pathol. 2022 02; 256(2):186-201.
Score: 0.027
-
Therapeutic Targeting of Nemo-like Kinase in Primary and Acquired Endocrine-resistant Breast Cancer. Clin Cancer Res. 2021 05 01; 27(9):2648-2662.
Score: 0.026
-
TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 versus 24 Weeks in Patients with HER2-Positive Breast Cancer. Clin Cancer Res. 2020 02 15; 26(4):821-827.
Score: 0.023
-
Loss of heterozygosity at D14S62 and metastatic potential of breast cancer. J Natl Cancer Inst. 1999 Aug 18; 91(16):1391-7.
Score: 0.023
-
A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer. Ann Oncol. 2019 06 01; 30(6):927-933.
Score: 0.023
-
Mitosin (a new proliferation marker) correlates with clinical outcome in node-negative breast cancer. Cancer Res. 1997 Dec 15; 57(24):5505-8.
Score: 0.021
-
The SOX11 transcription factor is a critical regulator of basal-like breast cancer growth, invasion, and basal-like gene expression. Oncotarget. 2016 Mar 15; 7(11):13106-21.
Score: 0.018
-
Expression of ERG protein in prostate cancer: variability and biological correlates. Endocr Relat Cancer. 2015 Jun; 22(3):277-87.
Score: 0.017
-
Cross-species identification of a plasma microRNA signature for detection, therapeutic monitoring, and prognosis in osteosarcoma. Cancer Med. 2015 Jul; 4(7):977-88.
Score: 0.017
-
Intratumoral heterogeneity in a Trp53-null mouse model of human breast cancer. Cancer Discov. 2015 May; 5(5):520-33.
Score: 0.017
-
Semaphorin 4F as a critical regulator of neuroepithelial interactions and a biomarker of aggressive prostate cancer. Clin Cancer Res. 2013 Nov 15; 19(22):6101-11.
Score: 0.015
-
The small heat shock protein hsp27 is correlated with growth and drug resistance in human breast cancer cell lines. Cancer Res. 1993 Oct 01; 53(19):4443-8.
Score: 0.015
-
Estrogen and insulin-like growth factor-I (IGF-I) independently down-regulate critical repressors of breast cancer growth. Breast Cancer Res Treat. 2012 Feb; 132(1):61-73.
Score: 0.013
-
Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer. Breast Cancer Res. 2010; 12(3):R40.
Score: 0.012
-
Fibroblast growth factor receptor signaling dramatically accelerates tumorigenesis and enhances oncoprotein translation in the mouse mammary tumor virus-Wnt-1 mouse model of breast cancer. Cancer Res. 2010 Jun 15; 70(12):4868-79.
Score: 0.012
-
Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst. 2008 May 07; 100(9):672-9.
Score: 0.011
-
Primary breast cancer phenotypes associated with propensity for central nervous system metastases. Cancer. 2006 Aug 15; 107(4):696-704.
Score: 0.009
-
Clinical response to neoadjuvant docetaxel predicts improved outcome in patients with large locally advanced breast cancers. Breast Cancer Res Treat. 2005 Dec; 94(3):279-84.
Score: 0.009
-
Suppression of mammary tumorigenesis in transgenic mice by the RXR-selective retinoid, LGD1069. Cancer Epidemiol Biomarkers Prev. 2002 May; 11(5):467-74.
Score: 0.007